摘要
Objective:To study the efficacy of adjuvant tyrosine kinase inhibitor therapy for non-small cell lung cancer and its influence on survival outcome.Methods: 92 patients with NSCLC who were treated in our hospital between March 2010 and March 2012 were collected and divided into the control group (n=50) who underwent normal treatment and the observation group (n=42) who underwent adjuvant tyrosine kinase inhibitor therapy + routine treatment after the therapies were reviewed. Serum contents of malignant molecules were compared between two groups before and after treatment, and the median survival time after treatment and 3-year survival rate were recorded.Results: Before treatment, differences in serum levels of tumor markers, angiogenesis indexes and apoptosis molecules were not statistically significant between two groups of patients. After treatment, serum tumor markers CYFRA21-1, SCC, ProGRP and CA125 levels of observation group were lower than those of control group, angiogenesis indexes VEGF, bFGF and PCDGF levels were lower than those of control group while ES and PEDF levels were higher than those of control group, and apoptosis indexes sFas and sFasL levels were higher than those of control group. The median survival time of observation group after treatment was longer than that of control group, and 3-year survival rate was significantly higher than that of control group.Conclusion:Adjuvant tyrosine kinase inhibitor therapy for NSCLC can effectively reduce the malignant degree of tumor and optimize the long-term survival outcome.
